Opinion

Aaron Goodman: My prediction (American Society of Hematology 2023)

Photo from Aaron Goodman/X

Dec 9, 2023, 16:37

Aaron Goodman: My prediction (American Society of Hematology 2023)

Aaron Goodman shared a post on X/Twitter:

“My prediction is the plenary session at American Society of Hematology in 2033 will be 10 drugs vs 9 drugs in myeloma end point Minimal Residual Disease (MRD). IKRd vs KRd in newly diagnosed multiple myeloma.

For details, click here.
Source: Aaron Goodman/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.

Aaron Goodman American Society of Hematology cancer Minimal Residual Disease (MRD) multiple myeloma National Comprehensive Cancer Network OncoDaily Oncology University of California

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer